

LARS MAEGDEFESSEL PUBLICATIONS 2010**Peer-reviewed articles**

- 9) Leeper NJ, Raiesdana A, Kojima Y, Chun HJ, Azuma J, **Maegdefessel L**, Kundu RK, Quertermous T, Tsao PS, Spin JM. MicroRNA-26a is a novel regulator of vascular smooth muscle cell function. *J Cell Physiol.* 2010; 226:1035-43.
- 10) Azuma J, **Maegdefessel L**, Kitagawa T, Dalman RL, McConnell MV, Tsao PS. Assessment of elastase-induced murine abdominal aortic aneurysms: comparison of ultrasound imaging with in situ video microscopy. *J Biomed Biotechnol.* 2010; 25:21-41.
- 11) **Maegdefessel L**, Linde T, Krapiec F, Hamilton K, Steinseifer U, van Ryn J, Raaz U, Buerke M, Werdan K, Schlitt A. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves. *Thromb Res.* 2010; 126:196-200.
- 13) Raaz U, Kaeberich A, **Maegdefessel L**, Buerke M, Busshardt M, Schubert S, Russ M, Plehn A, Ebel H, Werdan K, Schlitt A. The direct thrombin inhibitor argatroban effectively prevents cardiac catheter thrombosis in vitro. *Thromb Haemost.* 2010; 103:808-14.
- 14) Raaz U, Buerke M, Busshardt M, **Maegdefessel L**, Plehn A, Hauröder B, Werdan K, Schlitt A. Efficacy of enoxaparin, certoparin and dalteparin in preventing cardiac catheter thrombosis: an in vitro approach. *J Thromb Thrombolysis.* 2010; 29:265-70.
- 15) Schlitt A, Schwaab B, Fingscheidt K, Lackner KJ, Heine GH, Vogt A, Buerke M, **Maegdefessel L**, Raaz U, Werdan K, Jiang XC. Serum phospholipid transfer protein activity after a high fat meal in patients with insulin-treated type 2 diabetes. *Lipids.* 2010; 45:129-35.

Peer-reviewed Review Articles

- 7) **Maegdefessel L**, Spin JM, Azuma J, Tsao PS. New options with dabigatran etexilate in anticoagulant therapy. *Vasc Health Risk Manag.* 2010; 6:339-49.
- 8) **Maegdefessel L**, Azuma J, Tsao PS. Modern role for clopidogrel in management of atrial fibrillation and stroke reduction. *Vasc Health Risk Manag.* 2010; 6:95-103.